company background image
DXB logo

Dimerix CHIA:DXB Stock Report

Last Price

AU$0.32

Market Cap

AU$175.7m

7D

-10.0%

1Y

75.0%

Updated

21 Dec, 2024

Data

Company Financials

Dimerix Limited

CHIA:DXB Stock Report

Market Cap: AU$175.7m

DXB Stock Overview

A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. More details

DXB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Earnings have declined by 29.5% per year over past 5 years

Makes less than USD$1m in revenue (A$583K)

Shareholders have been diluted in the past year


My Notes

Capture your thoughts, links and company narrative

Dimerix Limited Competitors

Imugene

ASX:IMU

AU$282.6m

Paradigm Biopharmaceuticals

ASX:PAR

AU$131.0m

Aroa Biosurgery

ASX:ARX

AU$234.5m

Immutep

ASX:IMM

AU$494.6m

Price History & Performance

Summary of share price highs, lows and changes for Dimerix
Historical stock prices
Current Share PriceAU$0.32
52 Week HighAU$0.67
52 Week LowAU$0.16
Beta0.52
1 Month Change-4.55%
3 Month Change-12.50%
1 Year Change75.00%
3 Year Change31.25%
5 Year Change142.31%
Change since IPO162.50%

Recent News & Updates

Recent updates

Shareholder Returns

DXBAU BiotechsAU Market
7D-10.0%0.1%-2.7%
1Y75.0%3.1%6.5%

Return vs Industry: DXB exceeded the Australian Biotechs industry which returned 3.1% over the past year.

Return vs Market: DXB exceeded the Australian Market which returned 6.5% over the past year.

Price Volatility

Is DXB's price volatile compared to industry and market?
DXB volatility
DXB Average Weekly Movement7.9%
Biotechs Industry Average Movement9.8%
Market Average Movement8.0%
10% most volatile stocks in AU Market16.8%
10% least volatile stocks in AU Market3.1%

Stable Share Price: DXB has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: DXB's weekly volatility has decreased from 13% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aNina Websterdimerix.com

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.

Dimerix Limited Fundamentals Summary

How do Dimerix's earnings and revenue compare to its market cap?
DXB fundamental statistics
Market capAU$175.72m
Earnings (TTM)-AU$17.08m
Revenue (TTM)AU$583.48k

301.2x

P/S Ratio

-10.3x

P/E Ratio

Is DXB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DXB income statement (TTM)
RevenueAU$583.48k
Cost of RevenueAU$0
Gross ProfitAU$583.48k
Other ExpensesAU$17.66m
Earnings-AU$17.08m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.031
Gross Margin100.00%
Net Profit Margin-2,926.43%
Debt/Equity Ratio0%

How did DXB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 14:17
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Dimerix Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution